A 12-year-old boy treated for SCID at 1 month of age by HLA-haploidentical BMT developed a lymphoproliferative disease of unknown etiology at the age of 9 years characterized by sustained, marked elevation of circulating CD8
GVHD can be completely prevented by using stem cell grafts depleted of mature T cells. 1 This approach has allowed the successful use of grafts from HLA-haploidentical donors, in particular in infants with SCID, leading to establishment of a tolerant and stable T cell system. 2, 3 In this report we present the management of a previous SCID patient in whom an established HLA-nonidentical T cell system became severely dysfunctional 9 years later for unknown reasons.
Case report
X-linked SCID was diagnosed in the patient at birth and was treated by T cell-depleted BMT without conditioning. The donor was the HLA-haploidentical father. The patient developed normal T cell immunity and a normal-sized thymus, while B cell functions remained weak, requiring regular immunoglobulin infusions. Donor cell chimerism was restricted to T cells (see Table 1 ). At the age of 9 years an elevated CD8 + T cell count was noted for the first time, and was confirmed several months later, in the absence of clinical abnormalities. Two years later, the patient presented with marked hepatosplenomegaly and with elevated levels of liver enzymes. The number of CD8 + T cells had further increased to 9 × 10 9 /l, while the number of CD4 + T cells had decreased to 0.65 × 10 9 /l. T cell responses to PHA and to recall antigens had become severely impaired. The patient did not present with fever, lymphadenopathy, weight loss or signs of systemic disease. A liver biopsy displayed signs of chronic-active hepatitis with diffuse infiltrations by CD8
+ T cells as well as perilobular fibrosis. Findings were not compatible with GVHD or viral disease. Herpes hominis virus 6 (HHV6) DNA was amplified from liver tissue, but not from blood or marrow. The majority of circulating T cells expressed CD8, alpha/beta T cell receptor (TCR) and HLA-DR. Analysis of the TCRBV repertoire by quantitative family-specific RT-PCR and spectratyping revealed normal TCRBV usage and normal CDR3 size distribution of CD4 + T cells but a skewed TCRBV usage and restricted CDR3 size distribution of CD8 + T cells. These findings reflected polyclonal expansion of CD8 + T cell populations. Since infection by HHV6 could not be completely ruled out as the cause of the liver disease, antiviral treatment with foscarnet was explored but was without effect. Immunosuppressive treatment with prednisolone led to some decrease of circulating CD8 + T cells; however, marked hepatosplen- Bone Marrow Transplantation omegaly persisted, and upon tapering the number of circulating CD8 + T cells increased again. Pathological findings remained unchanged in a repeat liver biopsy, whereas HHV6 was no longer detectable.
In the absence of alternative therapeutic options to reverse the immunopathological process and to treat the progressive liver disease, we performed a second BMT. Our aim was to replace the dysfunctional paternally derived T cell system. A younger sister was meanwhile available as a genotypically HLA-identical donor. The patient underwent immunosuppressive conditioning with fludarabine 40 mg/m 2 on 5 consecutive days (total dose 200 mg/m 2 , days −9 until −5) and rabbit anti-thymocyte globulin (Thymoglobulin; Merieux, France) at 10 mg/kg on 5 consecutive days (total dose 50 mg/kg, days −5 until −1). Unmanipulated marrow was transplanted, containing 1.3 × 10 8 CD3 + cells/kg body weight. As GVHD prophylaxis, mycophenolic acid was administered at 15 mg/kg per day for 1 month as well as prednisolone at 2 mg/kg per day during the first 2 weeks after BMT. The patient developed transient pancytopenia without requiring blood cell transfusions. There was no evidence of skin GVHD. Liver enzymes increased further during the second month, but subsequently decreased and normalized. The size of the liver and spleen decreased dramatically during the second month after BMT and became normal (Figure 1) . In a liver biopsy performed at day +100 infiltrations by T cells were markedly less prominent as compared to the findings prior to BMT. T cells in the liver were expanded in culture and chimerism of these cells was analyzed by interphase cytogenetics. A mixture of cells with chromosome constitution XX and XY, respectively, was observed, with predominance of the former. A repeat biopsy performed at day +270 revealed only small residual lymphocyte infiltrates, and expandable T cells were now exclusively female. In the blood, lymphocytes decreased to 0.2 × 10 9 /l after conditioning. Initially, recovering lymphocytes were predominantly CD8 + and of paternal origin. CD4 + T cells appeared at around 3 weeks after BMT, simultaneously with the initial detection of T cells of female genotype. At 3 months the T cells showed a regular distribution and normal in vitro function. Repeat chimerism studies showed that all blood cells, including B cells and granulocytes, were derived from the sister (Table 1) . At 2 years after transplantation the patient is in excellent health without evidence of liver disease and with normal immune functions.
Discussion
The basis of the severe T cell dysfunction developing in the patient several years after successful HLA-haploidentical BMT for SCID remained obscure. A malignant process could be ruled out based on the slow progression of the proliferative disorder for almost 2 years in the absence of other findings of systemic disease and the lack of monoclonality of proliferating lymphocytes. Could the complication reflect a profoundly dysregulated T cell system related to thymic dysfunction? The initial transplant had been performed without conditioning. An extremely small thymus, characteristic of SCID, had normalized in size, indicating repopulation by donor lymphoid precursor cells. However, donor lymphoid precursor cells may have failed to engraft permanently in the marrow, as was in fact demonstrated in a similar SCID patient in whom we were unable to detect donor CD34 + cells in the marrow, whereas the T cell system was completely restored. 4 As a consequence, seeding of the thymus by precursor cells may be severely restricted, which may impair long-term function of the thymus, and respectively, the T cell system.
In our patient an immunological strategy was explored to overcome the lymphoproliferative process. Mature T cells of the second donor, genotypically HLA-identical with the recipient, were expected to recognize and to attack the HLA-mismatched, paternally derived T cell system in the patient, whereas paternal T cells, tolerant to the recipient, should have a limited or no capacity to reject cells of the second donor. As this unidirectional graft-versus-graft reaction carried the risk of an abrupt and overwhelming inflammatory reaction in the liver, which was infiltrated by HLA-nonidentical donor T cells, immunosuppressive conditioning was applied prior to and for a limited period after transplantation. Indeed, transient further elevation of liver enzymes may have reflected such a reaction, which occurred at the time when immunosuppressive treatment was discontinued. It should be pointed out that conditioning did not lead to complete eradication of paternal T cells. Initally after transplantation, these cells persisted both in peripheral blood and in the liver, but were replaced by T cells of the second, HLA-identical donor after discontinuation of all immunosuppressive treatment. We assume that at this stage T cells of the second donor became capable of eradicating the dysfunctional T cell system. The treatment led to complete resolution of the hepatopathy and to establishment of a competent immune system, validating the therapeutic strategy which was chosen to treat a lifethreatening complication.
